Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. Ana...

Full description

Saved in:
Bibliographic Details
Published in:BMC medicine 2013-01, Vol.11 (1), p.23-23, Article 23
Main Authors: Jit, Mark, Levin, Carol, Brisson, Marc, Levin, Ann, Resch, Stephen, Berkhof, Johannes, Kim, Jane, Hutubessy, Raymond
Format: Article
Language:English
Subjects:
Cancer
Correspondence
Cost analysis
Costs and Cost Analysis - methods
Data processing
Developing Countries
economic evaluation
Economic models
Economics
Epidemiology
Female
Human papillomavirus
Humans
Immunization Programs - economics
Infectious diseases
Low income groups
low- and middle-income countries
Medical screening
Papillomavirus Infections - complications
Papillomavirus Infections - economics
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - economics
Uterine Cervical Neoplasms - economics
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - prevention & control
Vaccination
Vaccination - economics
Vaccination - methods
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. Analysts informing policy decisions should address the following questions: 1) Is an economic analysis needed? 2) Should analyses address costs, epidemiological outcomes, or both? 3) If costs are considered, what sort of analysis is needed? 4) If outcomes are considered, what sort of model should be used? 5) How complex should the analysis be? 6) How should uncertainty be captured? 7) How should model results be communicated? Selecting the appropriate analysis is essential to ensure that all the important features of the decision problem are correctly represented, but that the analyses are not more complex than necessary. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries.
ISSN:1741-7015
1741-7015
DOI:10.1186/1741-7015-11-23